 |
市場調査レポート
商品コード
1270747
創薬アウトソーシングの世界市場 (2022-2028年)：薬剤タイプ・ワークフロー・治療分野・用途別の規模・シェア・成長分析・予測Global Drug Discovery Outsourcing Market Size, Share, Growth Analysis, By Drug Type, By Workflow, By Therapeutic area, By Application - Industry Forecast 2022-2028 |
||||||
| 創薬アウトソーシングの世界市場 (2022-2028年)：薬剤タイプ・ワークフロー・治療分野・用途別の規模・シェア・成長分析・予測 |
|
出版日: 2023年04月30日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
創薬アウトソーシングの市場規模は、2021年に32億6,000万米ドル、2022年に35億米ドルを示し、2023年から2030年にかけての予測期間中は7.3%のCAGRで推移し、2030年には62億米ドルの規模に成長すると予測されています。
公的機関と民間企業との連携が進み、創薬プロセスのスピードアップが図られ、創薬アウトソーシングサービスの世界的な需要が高まっています。また、製薬・バイオ医薬品業界におけるR&D費の増加、分析試験サービスに対する需要の高まり、希少疾病・希少薬研究に対する取り組み、自社での医薬品開発コストの高さなどが、創薬サービス市場に新しい収益ポケットを生み出しています。
当レポートでは、世界の創薬アウトソーシングの市場を調査し、市場概要、市場への各種影響因子の分析、技術・イノベーションの動向、市場規模の推移・予測、各種区分・地域別の内訳、競合情勢、主要企業のプロファイルなどをまとめています。
目次
エグゼクティブサマリー
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 主要市場洞察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料分析
- イノベーションマトリックス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資分析
- 主要成功因子
- 競合の度合い
- 市場力学と見通し
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制状況
- ポーターの分析
- 将来のディスラプションに関するSkyquestの特別な洞察
世界の創薬アウトソーシング市場：薬剤タイプ別
- 市場概要
- 低分子
- 高分子
- 生物製剤
世界の創薬アウトソーシング市場：ワークフロー別
- 市場概要
- ターゲットの同定・スクリーニング
- ターゲットのバリデーション・機能性インフォマティクス
- リードの特定・候補の最適化
- 前臨床開発
- その他
世界の創薬アウトソーシング市場：治療分野別
- 市場概要
- 呼吸器系
- 腫瘍
- 眼科
- 血液
- 心血管系
- 内分泌
- 胃腸
- 免疫調節
- 抗感染症
- 中枢神経系
- 皮膚科
- 泌尿器系
世界の創薬アウトソーシング市場：用途別
- 市場概要
- 病院・診療所
- 医療ラボ
- その他
世界の創薬アウトソーシング市場：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋地域
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ地域
競合情勢
- トップ5社の比較
- 主要企業の位置付け
- 主要企業の採用戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア
- 主要企業プロファイル
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- WuXi AppTec Co., Ltd.
- Albany Molecular Research Inc. (AMRI)
- GVK Biosciences Private Limited
- Sygnature Discovery
- Pharmaron Beijing Co., Ltd
- WuXi Biologics (Cayman), Inc.
- Domainex Ltd.
- Thermo Fisher Scientific, Inc.
- Jubilant Biosys Ltd.
- Evotec SE
- Eurofins Discovery
- GenScript Biotech Corporation
Global Drug Discovery Outsourcing Market size was valued at USD 3.26 billion in 2021 and is poised to grow from USD 3.5 billion in 2022 to USD 6.2 billion by 2030, growing at a CAGR of 7.3% in the forecast period (2023-2030).
Rising collaborations between public and commercial entities speed up drug discovery procedures, increasing global demand for drug discovery outsourcing services. The ultimate goal of a preclinical drug discovery programme is to deliver one or more clinical candidate molecules that have sufficient evidence of biological activity at a disease-relevant target as well as sufficient safety and drug-like properties to be tested in humans.
Growing R&D expenditure in the pharmaceutical and biopharmaceutical industries, rising demand for analytical testing services, initiatives for rare disease and orphan drug research, and the high cost of in-house drug development are all creating new revenue pockets in the drug discovery services market.
Many pharmaceutical and biotechnology businesses partnered with CROs through long-term agreements, partnerships, and collaborations around the world to accelerate the R&D process. Eurofins Scientific SE (France), for example, launched Adaptive immune response models in May 2021 to study the immunological repercussions of SARS-CoV-2 and other viral diseases for drug discovery.
Top-down and bottom-up approaches were used to estimate and validate the size of global Drug Discovery Outsourcing Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.
Segments covered in this report
Global Drug Discovery Outsourcing Market is segmented on the basis of drug type, workflow, therapeutic area, application, and region. By drug type, the Drug Discovery Outsourcing Market is segmented into small molecule, large molecule, and biologics. By workflow, the Drug Discovery Outsourcing Market is segmented into Target Identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and others. By therapeutic area, the Drug Discovery Outsourcing Market is segmented into Respiratory system, oncology, ophthalmology, haematology, cardiovascular, endocrine, gastrointestinal, immunomodulation, anti-infective, central nervous system, dermatology, and genitourinary system. By application, the Drug Discovery Outsourcing Market is segmented into Hospitals & clinics, medical laboratories, and others. By region, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
Drivers
Increased investment in healthcare infrastructure development will create lucrative opportunities for the global drug discovery outsourcing market.
Pharmaceutical and biopharmaceutical businesses' increasing R&D expenditures are leading them to seek fully integrated or functional outsourcing services for drug research and development, from the early development stage to the late-stage development phase. Outsourcing has grown as a strategic solution to offset the shortage of in-house resources required for new product development as pharma businesses face great pressure to limit fixed costs. Large pharmaceutical corporations are shifting to a leaner business strategy that mainly relies on outsourcing. Most pharmaceutical and biopharmaceutical businesses outsource their testing services throughout R&D to increase profitability, meet drug development timeframes, and save money. This is evidenced by major pharmaceutical companies' recent deals with CROs that provide drug discovery and development services. As a result, rising pharmaceutical R&D spending fuels the growth of the drug discovery services industry.
Restraint
Stringent policies and high manufacturing costs will stymie the growth of the drug delivery outsourcing market.
The primary focus of regulatory bodies during drug approval is ensuring safety and efficacy, which significantly raises the cost of drug development and the final product. This aspect can have a substantial impact on medicine uptake in price-sensitive emerging markets. Aside from that, different legislations that protect product quality (such as GMP) frequently raise manufacturing prices. Animal testing in drug discovery is governed by strict restrictions. The most regularly employed animals in study are mice, rats, fish, amphibians, and reptiles. Concerns about the ethical use of animals in research have prompted governments to enact animal safety and use legislation, which poses various hurdles to the smooth operation of drug discovery research. Companies have been obliged to find alternative methods to reduce animal use. Novo Nordisk, for example, employs bio simulation, which entails employing computer models to imitate human biology. However, this has not been fully implemented throughout the market.
Market Trends
The escalation of cancer cases will shape the future of the global drug discovery outsourcing market.
As more small and medium-sized businesses outsource drug discovery services, the value chain of the drug discovery outsourcing market will see new growth prospects in the future years.
During the foreseeable period, oncology will lead worldwide demand since the burden of curing cancer remains a global duty.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
- Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
- Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
- Global Drug Discovery Outsourcing Market by Drug Type
- Market Overview
- Small Molecules
- Large molecules
- biologics
- Global Drug Discovery Outsourcing Market by Workflow
- Market Overview
- Target Identification & screening
- target validation & functional informatics
- lead identification & candidate optimization
- preclinical development
- others
- Global Drug Discovery Outsourcing Market by Therapeutic area
- Market Overview
- Respiratory system
- oncology
- ophthalmology
- haematology
- cardiovascular
- endocrine
- gastrointestinal
- immunomodulation
- anti-infective
- central nervous system
- dermatology
- genitourinary system
Global Drug Discovery Outsourcing Market by Application
- Market Overview
- Hospitals & clinics
- medical laboratories
- others
- Global Drug Discovery Outsourcing Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
- Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
- Key Company Profiles
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi AppTec Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Albany Molecular Research Inc. (AMRI)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GVK Biosciences Private Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sygnature Discovery
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pharmaron Beijing Co., Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- WuXi Biologics (Cayman), Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Domainex Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Jubilant Biosys Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Evotec SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eurofins Discovery
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GenScript Biotech Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
